|Bid||14.95 x 1100|
|Ask||14.98 x 800|
|Day's Range||14.70 - 15.18|
|52 Week Range||11.21 - 25.96|
|Beta (3Y Monthly)||2.47|
|PE Ratio (TTM)||12.52|
|Earnings Date||Feb 20, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.20|
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
After extended weakness, biotech stocks turned a corner along with the broader markets to close out the week. With just a session left, it looks less likely the sector ends in the black for the year. The ...
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients’ money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth depends on it. Regardless of the various methods used by elite investors like David Tepper and Dan Loeb, […]
Biotech Corcept develops drugs to treat cortisol activity, such as Cushing's disease. The chief drug is Korlym, also known as mifepristone.
HENDERSON, NV / ACCESSWIRE / December 13, 2018 / Here is a list of several Biotech companies in the news that could make investors profits heading into the holiday season. We are highlighting: Endonovo ...
Corcept Therapeutics Incorporated (CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow a patent covering the concomitant use of Korlym® and drugs from the class of medications known as strong CYP3A inhibitors to treat patients with hypercortisolism (Cushing’s syndrome). The patent will expire in 2037. “This patent covers an important finding of our research – that with proper dose modulation, Korlym can safely be administered in combination with medications that are strong CYP3A inhibitors,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / Shares of MYOS RENS and Corcept Therapeutics were two biotech stocks seeing huge gains in Tuesday’s trading session. MYOS RENS shares soared after news of its product being launched with The Vitamin Shoppe. The fact that a generic version of Corcept Therapeutics’ Korlym drug may not happen for a while had traders cheering and sending the stock higher.
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Corcept Therapeutics Incorporated (NASDAQ:CORT), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...
Corcept (CORT) delivered earnings and revenue surprises of 0.00% and -4.10%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Menlo Park, California-based company said it had net income of 14 cents per share. Earnings, adjusted for stock option expense and non-recurring costs, were 22 cents per share. The drug developer posted ...
MENLO PARK, Calif., Nov. 01, 2018 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a company engaged in the discovery, development and commercialization of drugs to treat.
In 1999 Joseph Belanoff was appointed CEO of Corcept Therapeutics Incorporated (NASDAQ:CORT). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...
Anyone researching Corcept Therapeutics Incorporated (NASDAQ:CORT) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...